相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
Eftychia Stavrakaki et al.
CANCERS (2021)
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma A Randomized Clinical Trial
Timothy F. Cloughesy et al.
JAMA ONCOLOGY (2020)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Jacob M. Ricca et al.
MOLECULAR THERAPY (2018)
Durable complete responses in some recurrent highgrade glioma patients treated with Toca 511+Toca FC
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2018)
Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment
Wouter B. L. van den Bossche et al.
NEURO-ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Robert A. Berkeley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Karsten Geletneky et al.
MOLECULAR THERAPY (2017)
The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity
Anne Kleijn et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schoenfeld et al.
MOLECULAR THERAPY (2015)
Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
Hong Jiang et al.
PLOS ONE (2014)
The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
Anne Kleijn et al.
PLOS ONE (2014)
Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
Kimberly P. Kicielinski et al.
MOLECULAR THERAPY (2014)
Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
Christopher Jackson et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Central Memory CD4(+) T Cells Dominate the Normal Cerebrospinal Fluid
Marieke T. de Graaf et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)
In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines
Hani J. Marcus et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
Michael P. Gustafson et al.
NEURO-ONCOLOGY (2010)
Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas
Hong Jiang et al.
CURRENT GENE THERAPY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death
Marta M. Alonso et al.
MOLECULAR THERAPY (2008)
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
Peter Forsyth et al.
MOLECULAR THERAPY (2008)
Differential effects of combined Ad5-Δ24RGD and radiation therapy in In vitro versus In vivo models of malignant glioma
Martine L. M. Lamfers et al.
CLINICAL CANCER RESEARCH (2007)
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter
Marta M. Alonso et al.
CANCER RESEARCH (2007)
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
EA Chiocca et al.
MOLECULAR THERAPY (2004)
Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
Y Chen et al.
HUMAN GENE THERAPY (2000)
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
JM Markert et al.
GENE THERAPY (2000)
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
J Fueyo et al.
ONCOGENE (2000)
分享论文
